Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab

Cancer Research

Volumn 75, Issue 23, 2015, Pages 5084-5092

  Koguchi, Yoshinobu ^a   Hoen, Helena M ^a   Bambina, Shelly A ^a   Rynning, Michael D ^b   Fuerstenberg, Richard K ^b   Curti, Brendan D ^a   Urba, Walter J ^a   Milburn, Christina ^c   Bahjat, Frances Rena ^c   Korman, Alan J ^c   Bahjat, Keith S ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b R and D Systems Inc   (United States)

^c Bristol Myers Squibb   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL11 CHEMOKINE; GLYCOPROTEIN GP 100 PEPTIDE VACCINE; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 POLYPEPTIDE RELATED CHAIN A; PEPTIDE VACCINE; POLYPEPTIDE; UNCLASSIFIED DRUG; CANCER VACCINE; CXCL11 PROTEIN, HUMAN; GP100(209-2M) VACCINE; HLA ANTIGEN CLASS 1; MHC CLASS I-RELATED CHAIN A; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CHEMOKINE CXCL11; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84955285589     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2303     Document Type: Article

References (35)

1. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: A novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013; 1291: 1-13.
2. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229: 12-26.
3. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells codefines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210: 1695-710.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
5. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2014; 65: 185-202.
6. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24: 2174-80.
7. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61.
8. Curti BD, Urba WJ. Clinical deployment of antibodies for treatment of melanoma. Mol Immunol 2015; 67: 18-27.
9. Boyles AL, Harris SF, Rooney AA, Thayer KA. Forest plot viewer: A new graphing tool. Epidemiology 2011; 22: 746-7.
10. Wilgenhof S, FourDuS, Vandenbroucke F, Everaert H, Salmon I, Lienard D, et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013; 36: 215-22.
11. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, Curvietto M, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014; 63: 675-83.
12. Kelderman S, Heemskerk B, van Tinteren H, van den Brom RRH, Hospers GAP, van den Eertwegh AJM, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63: 449-58.
13. Di Giacomo AM, Danielli R, Calabro L, Bertocci E, Nannicini C,Giannarelli D, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2010; 60: 467-77.
14. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013; 24: 1697-703.
15. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, et al. Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015; 25: 208-24.
16. Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014; 2: 127-32.
17. Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer 2010; 116: 1767-75.
18. Mouawad R, Spano J-P, Khayat D. Old and new serological biomarkers in melanoma: Where we are in 2009. Melanoma Res 2010; 20: 67-76.
19. Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol 2015; 38: 252-8.
20. Simon R. Clinical trials for predictive medicine: New challenges and paradigms. Clin Trials 2010; 7: 516-24.
21. Van Raemdonck K, Van Den Steen PE, Liekens S, Van Damme J, Struyf S. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev 2014; 26: 311-27.
22. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity 2013; 39: 11-26.
23. Ji R-R, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2011; 61: 1019-31.
24. Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD. CXCR3 internalization following T cell-endothelial cell contact: Preferential role of IFN-inducible T cell chemoattractant (CXCL11). J Immunol 2001; 167: 7084-93.
25. Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest 2014; 124: 2009-22.
26. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: Positioning cells for host defense and immunity. Annu Rev Immunol 2014; 32: 659-702.
27. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cellhomeostasis and function during type 1 inflammation. Nat Immunol 2009; 10: 595-602.
28. Billottet C, Quemener C, Bikfalvi A. CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta 2013; 1836: 287-95.
29. Robledo MM, Bartolome RA, Longo N, Rodríguez-Frade JM, Mellado M, Longo I, et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001; 276: 45098-105.
30. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: Correlation with clinicopathological prognostic factors. J Clin Pathol 2007; 60: 596-9.
31. Longo-Imedio MI, Longo N, Trevino I, Lazaro P, Sanchez-Mateos P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 2005; 117: 861-5.
32. Le Bert N, Gasser S. Advances in NKG2D ligand recognition and responses by NK cells. Immunol Cell Biol 2014; 92: 230-6.
33. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413-41.
34. Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, et al. The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity. Front Immun 2013; 4: 490.
35. Labiano S, Palazon A, Melero I. Immune response regulation in the tumor microenvironment by hypoxia. Semin Oncol 2015; 42: 378-86.